Research Progress of Antibody-conjugated Drugs in Non-small Cell Lung Cancer

VernacularTitle:抗体偶联药物在非小细胞肺癌中的研究进展
Author: LIU YUNBO ¹ ; WEI SEN
Author Information

1. 300070 天津,天津医科大学
Keywords: Lung neoplasms; Antibody-drug conjugates; Human epidermal growth factor receptor 2; Human epi-dermal growth factor receptor 3; Trophoblast cell surface antigen 2
From: Chinese Journal of Lung Cancer 2024;27(6):431-440
CountryChina
Language:Chinese
Abstract: Lung cancer is the most common malignant tumor and the second most common malignant tumor in terms of mortality in the world.Non-small cell lung cancer(NSCLC)is the most common pathological type of lung cancer.Currently,the first-line standard treatment for advanced NSCLC is immunotherapy and targeted therapy.Although these treat-ments prolong the survival of patients,acquired drug resistance is still inevitable.Antibody-drug conjugates(ADCs)are a new type of anti-tumor drug made by coupling cytotoxic payloads to specific monoclonal antibodies via linkers.Compared with chemotherapy drugs,ADCs have the advantages of accurate recognition,local release,and high patient tolerance.In recent years,they have shown good clinical benefits in the treatment of NSCLC.This article provides an overview of the mechanism of action of ADCs,clinical studies progress in advanced NSCLC,and existing problems and challenges.